Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

Summary Background In patients with platinum-sensitive recurrent serous ovarian cancer, maintenance monotherapy with the PARP inhibitor olaparib significantly improves progression-free survival versus placebo. We assessed the effect of maintenance olaparib on overall survival in patients with platin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2016-11, Vol.17 (11), p.1579-1589
Hauptverfasser:	Ledermann, Jonathan A, Prof, Harter, Philipp, MD, Gourley, Charlie, Prof, Friedlander, Michael, Prof, Vergote, Ignace, Prof, Rustin, Gordon, Prof, Scott, Clare, PhD, Meier, Werner, Prof, Shapira-Frommer, Ronnie, MD, Safra, Tamar, MD, Matei, Daniela, MD, Fielding, Anitra, MBChB, Spencer, Stuart, MSc, Rowe, Philip, MSc, Lowe, Elizabeth, MD, Hodgson, Darren, PhD, Sovak, Mika A, MD, Matulonis, Ursula, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use BRCA1 Protein - genetics BRCA2 Protein - genetics Cancer therapies Chemotherapy Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - mortality Deoxyribonucleic acid DNA Double-Blind Method Female Gynecology Hematology, Oncology and Palliative Medicine Humans Middle Aged Mutation Neoplasm Recurrence, Local - drug therapy Oncology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Phthalazines - adverse effects Phthalazines - therapeutic use Piperazines - adverse effects Piperazines - therapeutic use Platinum Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Population Survival analysis Tumors Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!